How to buy Amdocs (DOX) shares in the UK

Learn how to easily invest in Amdocs shares.

Amdocs Limited (DOX) is a leading software-infrastructure business based in the US. It opened the day at $76.86 after a previous close of $77.11. During the day the price has varied from a low of $76.65 to a high of $77.51. The latest price was $77.11 (25 minute delay). Amdocs is listed on the NASDAQ and employs 28,000 staff. All prices are listed in US Dollars.

How to buy shares in Amdocs

  1. Choose a platform. If you're a beginner, our share-dealing table below can help you choose.
  2. Open your account. You'll need your ID, bank details and national insurance number.
  3. Confirm your payment details. You'll need to fund your account with a bank transfer, debit card or credit card.
  4. Search the platform for stock code: DOX in this case.
  5. Research Amdocs shares. The platform should provide the latest information available.
  6. Buy your Amdocs shares. It's that simple.
The whole process can take as little as 15 minutes.

How has coronavirus impacted Amdocs's share price?

Since the stock market crash that started in February 2020, Amdocs's share price has had significant negative movement.

Its last market close was $70.77, which is 3.25% down on its pre-crash value of $73.15 and 60.66% up on the lowest point reached during the March 2020 crash when the shares fell as low as $44.05.

If you had bought $1,000 worth of Amdocs shares at the start of February 2020, those shares would have been worth $635.67 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $975.21.

Amdocs share price (NASDAQ:DOX)

Use our graph to track the performance of DOX stocks over time.

Amdocs shares at a glance

Information last updated 2021-07-30.
Previous close$77.11
Change %0%
Information last updated 2021-12-05.
52-week range$64.812 - $81.73
50-day moving average$75.8928
200-day moving average$77.1532
Wall St. target price$87.75
PE ratio13.1372
Dividend yield$1.407 (1.99%)
Earnings per share (TTM)$5.32
eToro Free Stocks

Invest in Amdocs shares with 0% commission

Other fees apply. Your capital is at risk.

  • Unlimited trades, with no dealing charges or management fees
  • Pay no stamp duty on UK shares (saving 0.5%)
  • Create an account today in a few minutes
Capital at risk

Fees for buying 10x Amdocs shares with popular platforms

Both exchange rates and share prices fluctuate in real time, so the costs presented here should be considered as a guide only. They do not incorporate stamp duty. Always refer to the platform itself for availability and pricing – which may differ from our information.

Platform Platform fee Min. initial deposit Trading fee estimate
eToro Free Stocks logo £0 $50 £2.92
£586.80 total
Capital at risk
Fineco logo £0 No minimum £5.84
£589.72 total
Capital at risk
Degiro Share Dealing logo £0 £0.58
£584.46 total
Capital at risk
Stake logo £0 £50 £2.92
£586.80 total
Capital at risk
IG Share Dealing logo £0 £250 £10.53
£594.41 total
Capital at risk
Hargreaves Lansdown Fund and Share Account logo £0 £1 £17.79
£601.67 total
Capital at risk
interactive investor Trading Account logo £9.99 per month No minimum £16.75
£600.63 total
Capital at risk
Halifax Share Dealing Account logo £36 per year £20 £16.80
£600.68 total
Capital at risk

Full comparison of share dealing platforms

All investing should be regarded as longer term. The value of your investments can go up and down, and you may get back less than you invest. Past performance is no guarantee of future results. If you’re not sure which investments are right for you, please seek out a financial adviser. Capital at risk.

Is it a good time to buy Amdocs stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Is Amdocs under- or over-valued?

Valuing a stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of overall performance. However, analysts commonly use some key metrics to help gauge value.

P/E ratio

Amdocs's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 13x. In other words, Amdocs shares trade at around 13x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

PEG ratio

Amdocs's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.3443. A PEG ratio over 1 can be interpreted as meaning shares are overvalued at the current rate of growth, or may anticipate an acceleration in growth.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Amdocs's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.


Amdocs's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $826.5 million (£0.0 million).

The EBITDA is a measure of a Amdocs's overall financial performance and is widely used to measure a its profitability.


Revenue TTM $4.3 billion
Operating margin TTM 14.4%
Gross profit TTM $1.5 billion
Return on assets TTM 6.01%
Return on equity TTM 18.86%
Profit margin 16.05%
Book value $28.531
Market capitalisation $9 billion

TTM: trailing 12 months

Environmental, social and governance track record

Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Amdocs.

Total ESG risk score

Amdocs's total ESG risk: 20.97

Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Amdocs's overall score of 20.97 (as at 01/01/2019) is pretty good – landing it in it in the 21st percentile of companies rated in the same sector.

ESG scores are increasingly used to estimate the level of risk a company like Amdocs is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).

Environmental score

Amdocs's environmental score: 6.71/100

Amdocs's environmental score of 6.71 puts it squarely in the 6th percentile of companies rated in the same sector. This could suggest that Amdocs is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.

Social score

Amdocs's social score: 15.33/100

Amdocs's social score of 15.33 puts it squarely in the 6th percentile of companies rated in the same sector. This could suggest that Amdocs is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.

Governance score

Amdocs's governance score: 10.44/100

Amdocs's governance score puts it squarely in the 6th percentile of companies rated in the same sector. That could suggest that Amdocs is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.

Controversy score

Amdocs's controversy score: 1/5

ESG scores also evaluate any incidences of controversy that a company has been involved in. A high-profile company, Amdocs scored a 1 out of 5 for controversy – the highest score possible, reflecting that Amdocs has managed to keep its nose clean.

Environmental, social, and governance (ESG) summary

Amdocs Limited was last rated for ESG on: 2019-01-01.

Total ESG score 20.97
Total ESG percentile 20.5
Environmental score 6.71
Environmental score percentile 6
Social score 15.33
Social score percentile 6
Governance score 10.44
Governance score percentile 6
Level of controversy 1

Amdocs share dividends


Dividend yield: 1.99% of stock value


Forward annual dividend yield: 2.06% of stock value


Dividend payout ratio: 30% of net profits

Amdocs has recently paid out dividends equivalent to 1.99% of its share value annually.

Amdocs has paid out, on average, around 30% of recent net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 2.06% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), shareholders could enjoy a 2.06% return on their shares, in the form of dividend payments. In Amdocs's case, that would currently equate to about $1.407 per share.

While Amdocs's payout ratio might seem fairly standard, it's worth remembering that it may be investing much of the rest of its net profits in future growth.

Amdocs's most recent dividend payout was on 28 January 2022. The latest dividend was paid out to all shareholders who bought their shares by 30 December 2021 (the "ex-dividend date").

Share price volatility

Over the last 12 months, Amdocs's shares have ranged in value from as little as $64.812 up to $81.73. A popular way to gauge a stock's volatility is its "beta".

DOX.US volatility(beta: 0.77)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Amdocs's is 0.7662. This would suggest that Amdocs's shares are less volatile than average (for this exchange).

Win £500 to get your trading started

Subscribe to trending stock alerts for a chance to win

By submitting, you agree to the Finder Privacy and Cookies Policy and Terms of Use

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site